位置:首页 > 产品库 > Fosifloxuridine nafalbenamide
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Fosifloxuridine nafalbenamide
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Fosifloxuridine nafalbenamide图片
规格:98%
分子量:613.53
包装与价格:
包装价格(元)
5mg询价
10mg询价
25mg询价
50mg询价
100mg询价

Fosifloxuridine nafalbenamide (NUC-3373) 属于嘧啶核苷酸类似物,是一种胸腺嘧啶合酶 (Thymidylate synthase) 抑制剂。Fosifloxuridine nafalbenamide 具有抗癌活性。Fosifloxuridine nafalbenamide 具有诱发宿主免疫反应和增强免疫治疗的潜力。
货号:ajcx34134
CAS:1332837-31-6
分子式:C29H29FN3O9P
分子量:613.53
溶解度:DMSO : 100 mg/mL (162.99 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunotherapy[1][2].

Fosifloxuridine nafalbenamide induces the release of damage-associated molecular patterns (DAMPs), with increased expression of calreticulin (CRT) at the cell surface and concomitant loss of nuclear nuclear high mobility group box protein 1 (HMGB1)[1].

Fosifloxuridine nafalbenamide exhibits anti-cancer activity in HT-29 nude mouse xenograft models[2].

[1]. Fiona G. McKissock, et al. Abstract 1848: NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells. Cancer Res August 15 2020 (80) (16 Supplement) 1848.
[2]. Essam A. Ghazaly, et al. Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival. Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) B46.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024